Andie Collier - Galera Therapeutics Chief Officer
Executive
Andie Collier is Chief Officer of Galera Therapeutics
| Phone | 610 725 1500 |
| Web | https://www.galeratx.com |
Galera Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5929) % which means that it has lost $0.5929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.6311) %, meaning that it created substantial loss on money invested by shareholders. Galera Therapeutics' management efficiency ratios could be used to measure how well Galera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Galera Therapeutics currently holds 152.3 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Galera Therapeutics has a current ratio of 4.92, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Galera Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Galera Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Galera Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Galera to invest in growth at high rates of return. When we think about Galera Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Emil MD | Terns Pharmaceuticals | 45 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| Kirk MD | PDS Biotechnology Corp | 73 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 77 | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Adam JD | Day One Biopharmaceuticals | 58 | |
| Stephen MBA | Inozyme Pharma | 66 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Melita Jung | Terns Pharmaceuticals | 48 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Soojin Kim | Inozyme Pharma | N/A | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| JD Esq | Acumen Pharmaceuticals | 54 | |
| Andrew Gengos | Terns Pharmaceuticals | 61 | |
Management Performance
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 |
Galera Therapeutics Leadership Team
Elected by the shareholders, the Galera Therapeutics' board of directors comprises two types of representatives: Galera Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galera. The board's role is to monitor Galera Therapeutics' management team and ensure that shareholders' interests are well served. Galera Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galera Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mel MD, President CEO | ||
| Dr MBA, CoFounder COO | ||
| Jennifer Esq, Chief Secretary | ||
| Andie Collier, Chief Officer | ||
| FACS FACS, Chief Officer | ||
| Christopher Degnan, Chief Officer | ||
| PharmD MBA, Chief Officer | ||
| Jon MD, Ex Officer | ||
| Dennis Riley, Emeritus Officer | ||
| Judy Schnyder, Senior Management |
Galera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Galera Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 146.68 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 36.15 % | ||||
| Shares Owned By Institutions | 18.95 % | ||||
| Number Of Shares Shorted | 2.12 M | ||||
| Price To Earning | (0.78) X | ||||
| Price To Book | 29.39 X | ||||
| EBITDA | (46.69 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |